The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Trend Is Expected For The Neurogenic Detrusor Overactivity Market From 2026 To 2030?
The market size for neurogenic detrusor overactivity has experienced robust growth in recent years. It is anticipated to increase from $1.82 billion in 2025 to $1.97 billion in 2026, at a compound annual growth rate (CAGR) of 7.9%. The expansion observed during prior periods can be attributed to factors such as limited treatment options for NDO, a reliance on conventional surgical interventions, the increasing prevalence of neurogenic bladder disorders, growing hospital and urology clinic infrastructure, and a lack of patient and caregiver education.
The neurogenic detrusor overactivity market is projected to experience substantial growth over the next few years. It is expected to reach $2.63 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This expansion during the forecast period can be attributed to the development of novel pharmacological therapies, advancements in minimally invasive surgical procedures, the integration of neuromodulation devices, the increasing adoption of continuous patient monitoring technologies, and rising investment in long-term care and rehabilitation services. Major trends anticipated in this period include the growing uptake of antimuscarinic and beta-3 adrenergic agonists, increased utilization of neuromodulation and minimally invasive therapies, the expansion of behavioral therapy and patient training programs, a growing focus on urodynamic and ultrasound monitoring, and an increasing awareness of quality of life assessment and long-term care.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24619&type=smp
What Important Drivers Are Powering The Neurogenic Detrusor Overactivity Market Growth?
The increasing occurrence of neurological disorders is projected to boost the expansion of the neurogenic detrusor overactivity market in the future. Neurological disorders are health conditions impacting the brain, spinal cord, or nerves, resulting in issues with movement, sensation, thinking, or other bodily functions. Their prevalence is growing due to extended lifespans, which heightens the risk of age-related brain deterioration. Neurogenic detrusor overactivity (NDO) is a bladder problem frequently linked to neurological disorders like spinal cord injury, multiple sclerosis, and Parkinson’s disease. These conditions interfere with normal nerve communication between the brain and bladder, causing uncontrolled bladder contractions. As an example, a study released by the American Academy of Neurology (AAN), a US-based neurology and neuroscience organization, indicated in April 2024 that global brain disorder cases are expected to reach 4.9 billion by 2050, marking a 22% rise from around 4 billion cases in 2021. Consequently, the growing number of neurological disorders is fueling growth in the neurogenic detrusor overactivity market.
What Are The Major Segment Categories Within The Neurogenic Detrusor Overactivity Market?
The neurogenic detrusor overactivity market covered in this report is segmented –
1) By Types: Non-Surgical Treatment, Surgical Treatment, Follow-Up Treatment
2) By Application: Adult, Child
3) By End-User: Hospitals, Urology Clinics, Rehabilitation Centers, Private Practices, Long-Term Care Facilities
Subsegments:
1) By Non-Surgical Treatment: Antimuscarinic Drugs, Beta-3 Adrenergic Agonists, Behavioral Therapy, Neuromodulation, Clean Intermittent Catheterization, Intravesical Therapies
2) By Surgical Treatment: Botulinum Toxin Injection, Augmentation Cystoplasty, Urinary Diversion, External Sphincterotomy, Artificial Urinary Sphincter Implantation
3) By Follow-Up Treatment: Urodynamic Evaluation, Ultrasound Monitoring, Laboratory Tests, Ongoing Catheterization, Repeat Botulinum Toxin Injections, Patient and Caregiver Training, Quality of Life Assessment
What Trends Are Affecting The Neurogenic Detrusor Overactivity Market Dynamics?
Leading companies in the neurogenic detrusor overactivity (NDO) treatment market are focusing on the development of advanced generic therapeutics, such as beta-3 adrenergic receptor agonists, to provide effective and more affordable bladder control solutions. These beta-3 adrenergic receptor agonists, exemplified by mirabegron, operate by relaxing the detrusor muscle within the bladder, thereby increasing its capacity and mitigating symptoms like urgency and incontinence. For instance, in April 2024, Lupin Ltd., an India-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (USFDA) to introduce Mirabegron, the generic form of Myrbetriq, in the United States. As a sophisticated once-daily oral treatment, Mirabegron offers a convenient and efficient therapeutic choice for pediatric patients experiencing overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). This approval highlights Lupin’s dedication to improving access to high-quality, cost-effective generic medications in vital therapeutic domains.
Which Firms Are Competing In The Neurogenic Detrusor Overactivity Market?
Major companies operating in the neurogenic detrusor overactivity market are Astellas Pharma Inc., Medtronic plc, Ipsen, Coloplast A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Aurobindo Pharma Limited, Hugel Inc., Abbott Laboratories, Boston Scientific Corporation, Cook Medical, Convatec Group plc, B. Braun Melsungen AG, Teleflex Incorporated, Olympus Corporation, Karl Storz SE & Co. KG, Laborie Medical Technologies, Wellspect HealthCare (DENTSPLY Sirona), Hollister Incorporated, Uroplasty Inc., Endo Pharmaceuticals Inc., Ferring Pharmaceuticals, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Zydus Lifesciences Ltd.
Access The Complete Neurogenic Detrusor Overactivity Market Report:
Which Region Is The Dominant Market In The Neurogenic Detrusor Overactivity Market?
North America was the largest region in the neurogenic detrusor overactivity market in 2025. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Neurogenic Detrusor Overactivity Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24619&type=smp
Browse Through More Reports Similar to the Global Neurogenic Detrusor Overactivity Market 2026, By The Business Research Company
Peripheral Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Neurotoxin Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurotoxin-global-market-report
Diabetic Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model